Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc.AMRX · Entity 820 | Director | May 06, 2019 | May 08, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Amneal Pharmaceuticals, Inc.
Report date May 06, 2019 · Filed May 08, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 6,107 |
Reported balance
After 2019-05-08 transaction · row 1
1 source rowRow 1 · 2019-05-08 · Exercise / conversion · Acquired 6,107 · Balance 6,107 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $14.05 · Expires 2029-05-06 | Direct | 28,044 |
Reported balance
After 2019-05-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-05-06 · Grant · Acquired 28,044 · Balance 28,044 F2: The option vests on the later of (i) the day immediately preceeding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 6,459 |
Reported balance
After 2019-05-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-05-06 · Grant · Acquired 6,459 · Balance 6,459 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3: Restricted stock units vest on the later of (i) the day immediately preceeding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Restricted stock units have no expiration date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-05-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-05-08 · Exercise / conversion · Disposed 6,107 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4: On May 7, 2018, the reporting person was granted 6,107 restricted stock units vesting on May 8, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F2: The option vests on the later of (i) the day immediately preceeding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant.
F3: Restricted stock units vest on the later of (i) the day immediately preceeding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Restricted stock units have no expiration date.
F4: On May 7, 2018, the reporting person was granted 6,107 restricted stock units vesting on May 8, 2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 08, 2019 Filed May 8, 2019 21:46 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 6,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001723128-19-000066 · wf-form4_155735194769192.xml · derivative · entry 4 Greene Jean Selden · CIK 0001738015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 6,107 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: On May 7, 2018, the reporting person was granted 6,107 restricted stock units vesting on May 8, 2019. F4 · derivative.expiration_date: On May 7, 2018, the reporting person was granted 6,107 restricted stock units vesting on May 8, 2019. Read SEC document |
| May 08, 2019 Filed May 8, 2019 21:46 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 6,107 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001723128-19-000066 · wf-form4_155735194769192.xml · nonDerivative · entry 1 Greene Jean Selden · CIK 0001738015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,107 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| May 06, 2019 Filed May 8, 2019 21:46 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 6,459 | $0.00 | $0.00 |
DisclosureSEC source: 0001723128-19-000066 · wf-form4_155735194769192.xml · derivative · entry 3 Greene Jean Selden · CIK 0001738015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,459 Underlying: Class A Common Stock · 6,459 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3 · derivative.exercise_date: Restricted stock units vest on the later of (i) the day immediately preceeding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Restricted stock units have no expiration date. F3 · derivative.expiration_date: Restricted stock units vest on the later of (i) the day immediately preceeding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Restricted stock units have no expiration date. Read SEC document |
| May 06, 2019 Filed May 8, 2019 21:46 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantStock Option · Derivative | 28,044 | $0.00 Strike: $14.05 | $0.00 |
DisclosureSEC source: 0001723128-19-000066 · wf-form4_155735194769192.xml · derivative · entry 2 Greene Jean Selden · CIK 0001738015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,044 Underlying: Class A Common Stock · 28,044 shares Expires 2029-05-06 F2 · derivative.exercise_date: The option vests on the later of (i) the day immediately preceeding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Read SEC document |
| May 07, 2018 Filed May 9, 2018 22:41 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 6,107 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-012163 · doc4.xml · derivative · entry 2 Greene Jean Selden · CIK 0001738015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,107 Underlying: Class A Common Stock · 6,107 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on May 07, 2019 and have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on May 07, 2019 and have no expiration date. Read SEC document |
| May 07, 2018 Filed May 9, 2018 22:41 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantStock Option · Derivative | 24,977 | $0.00 Strike: $15.01 | $0.00 |
DisclosureSEC source: 0000899243-18-012163 · doc4.xml · derivative · entry 1 Greene Jean Selden · CIK 0001738015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,977 Underlying: Class A Common Stock · 24,977 shares Expires 2028-05-07 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on May 07, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.